Vitamin D, vitamin D-binding protein, free vitamin D and COVID-19 mortality in hospitalized patients.
COVID-19 mortality
bioavailable vitamin D
free vitamin D
vitamin D
vitamin D–binding protein
Journal
The American journal of clinical nutrition
ISSN: 1938-3207
Titre abrégé: Am J Clin Nutr
Pays: United States
ID NLM: 0376027
Informations de publication
Date de publication:
01 05 2022
01 05 2022
Historique:
received:
24
09
2021
accepted:
27
01
2022
pubmed:
2
2
2022
medline:
10
5
2022
entrez:
1
2
2022
Statut:
ppublish
Résumé
Vitamin D deficiency has been associated with worse coronavirus disease 2019 (COVID-19) outcomes, but circulating 25-hydroxyvitamin D [25(OH)D] is largely bound to vitamin D-binding protein (DBP) or albumin, both of which tend to fall in illness, making the 25(OH)D status hard to interpret. Because of this, measurements of unbound ("free") and albumin-bound ("bioavailable") 25(OH)D have been proposed. We aimed to examine the relationship between vitamin D status and mortality from COVID-19. In this observational study conducted in Liverpool, UK, hospitalized COVID-19 patients with surplus sera available for 25(OH)D analysis were studied. Clinical data, including age, ethnicity, and comorbidities, were extracted from case notes. Serum 25(OH)D, DBP, and albumin concentrations were measured. Free and bioavailable 25(OH)D were calculated. Relationships between total, free, and bioavailable 25(OH)D and 28-day mortality were analyzed by logistic regression. There were 472 patients with COVID-19 included, of whom 112 (23.7%) died within 28 days. Nonsurvivors were older (mean age, 73 years; range, 34-98 years) than survivors (mean age, 65 years; range, 19-95 years; P = 0.003) and were more likely to be male (67%; P = 0.02). The frequency of vitamin D deficiency [25(OH)D < 50 nmol/L] was similar between nonsurvivors (71/112; 63.4%) and survivors (204/360; 56.7%; P = 0.15) but, after adjustments for age, sex, and comorbidities, increased odds for mortality were present in those with severe deficiency [25(OH)D < 25 nmol/L: OR, 2.37; 95% CI, 1.17-4.78] or a high 25(OH)D (≥100 nmol/L; OR, 4.65; 95% CI, 1.51-14.34) compared with a 25(OH)D value of 50-74 nmol/L (reference). Serum DBP levels were not associated with mortality after adjustments for 25(OH)D, age, sex, and comorbidities. Neither free nor bioavailable 25(OH)D values were associated with mortality. Vitamin D deficiency, as commonly defined by serum 25(OH)D levels (<50 nmol/L), is not associated with increased mortality from COVID-19, but extremely low (<25 nmol/L) and high (>100 nmol/L) levels may be associated with mortality risks. Neither free nor bioavailable 25(OH)D values are associated with mortality risk. The study protocol was approved by the London-Surrey Research Ethics Committee (20/HRA/2282).
Sections du résumé
BACKGROUND
Vitamin D deficiency has been associated with worse coronavirus disease 2019 (COVID-19) outcomes, but circulating 25-hydroxyvitamin D [25(OH)D] is largely bound to vitamin D-binding protein (DBP) or albumin, both of which tend to fall in illness, making the 25(OH)D status hard to interpret. Because of this, measurements of unbound ("free") and albumin-bound ("bioavailable") 25(OH)D have been proposed.
OBJECTIVES
We aimed to examine the relationship between vitamin D status and mortality from COVID-19.
METHODS
In this observational study conducted in Liverpool, UK, hospitalized COVID-19 patients with surplus sera available for 25(OH)D analysis were studied. Clinical data, including age, ethnicity, and comorbidities, were extracted from case notes. Serum 25(OH)D, DBP, and albumin concentrations were measured. Free and bioavailable 25(OH)D were calculated. Relationships between total, free, and bioavailable 25(OH)D and 28-day mortality were analyzed by logistic regression.
RESULTS
There were 472 patients with COVID-19 included, of whom 112 (23.7%) died within 28 days. Nonsurvivors were older (mean age, 73 years; range, 34-98 years) than survivors (mean age, 65 years; range, 19-95 years; P = 0.003) and were more likely to be male (67%; P = 0.02). The frequency of vitamin D deficiency [25(OH)D < 50 nmol/L] was similar between nonsurvivors (71/112; 63.4%) and survivors (204/360; 56.7%; P = 0.15) but, after adjustments for age, sex, and comorbidities, increased odds for mortality were present in those with severe deficiency [25(OH)D < 25 nmol/L: OR, 2.37; 95% CI, 1.17-4.78] or a high 25(OH)D (≥100 nmol/L; OR, 4.65; 95% CI, 1.51-14.34) compared with a 25(OH)D value of 50-74 nmol/L (reference). Serum DBP levels were not associated with mortality after adjustments for 25(OH)D, age, sex, and comorbidities. Neither free nor bioavailable 25(OH)D values were associated with mortality.
CONCLUSIONS
Vitamin D deficiency, as commonly defined by serum 25(OH)D levels (<50 nmol/L), is not associated with increased mortality from COVID-19, but extremely low (<25 nmol/L) and high (>100 nmol/L) levels may be associated with mortality risks. Neither free nor bioavailable 25(OH)D values are associated with mortality risk. The study protocol was approved by the London-Surrey Research Ethics Committee (20/HRA/2282).
Identifiants
pubmed: 35102371
pii: S0002-9165(22)00259-3
doi: 10.1093/ajcn/nqac027
pmc: PMC8903333
doi:
Substances chimiques
Albumins
0
Vitamin D-Binding Protein
0
Vitamins
0
Vitamin D
1406-16-2
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1367-1377Informations de copyright
© Crown copyright 2022.
Références
Crit Care Med. 2017 Feb;45(2):282-289
pubmed: 27632669
Clin Nutr. 2021 Apr;40(4):2469-2472
pubmed: 33187772
J Bone Miner Res. 2014 Sep;29(9):2024-31
pubmed: 24677358
J Endocrinol Invest. 2021 Apr;44(4):765-771
pubmed: 32772324
J Pediatr. 2018 Dec;203:416-422.e1
pubmed: 30243543
J Immunol. 2010 Oct 15;185(8):4948-58
pubmed: 20855882
Postgrad Med J. 2021 Jul;97(1149):442-447
pubmed: 32855214
PLoS One. 2017 Feb 16;12(2):e0170791
pubmed: 28207791
Ann Intern Med. 2021 Feb;174(2):145-156
pubmed: 33284677
PLoS One. 2012;7(1):e30773
pubmed: 22292037
R Soc Open Sci. 2020 Dec 1;7(12):201912
pubmed: 33489300
Am J Clin Nutr. 2012 Jan;95(1):91-100
pubmed: 22170374
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Front Endocrinol (Lausanne). 2019 May 28;10:317
pubmed: 31191450
Osteoporos Int. 2017 Aug;28(8):2457-2464
pubmed: 28466136
Eur J Clin Nutr. 2021 Jun;75(6):980-987
pubmed: 32855522
J Biol Chem. 1992 May 15;267(14):10177-83
pubmed: 1374401
J Am Nutr Assoc. 2022 Feb;41(2):201-206
pubmed: 33605826
J Clin Endocrinol Metab. 2012 Aug;97(8):2644-52
pubmed: 22573406
Nutrients. 2015 May 29;7(6):4240-70
pubmed: 26035247
BMJ Nutr Prev Health. 2020 Jun 14;3(1):118-120
pubmed: 33235975
Front Endocrinol (Lausanne). 2019 Oct 24;10:718
pubmed: 31708871
Proc Natl Acad Sci U S A. 2021 Jan 7;118(1):
pubmed: 33323525
J Steroid Biochem Mol Biol. 2019 Mar;187:152-159
pubmed: 30476590
Am J Clin Nutr. 2007 Mar;85(3):860-8
pubmed: 17344510
Am J Clin Nutr. 2021 Aug 2;114(2):598-604
pubmed: 34020451
Adv Nutr. 2021 Oct 1;12(5):1636-1658
pubmed: 33751020
Am Surg. 2017 Nov 1;83(11):1220-1227
pubmed: 29183523
Panminerva Med. 2023 Mar;65(1):23-29
pubmed: 33494567
Thorax. 2022 Jan;77(1):65-73
pubmed: 34580193
Ann N Y Acad Sci. 2018 Oct;1430(1):44-79
pubmed: 30225965
Eur J Nutr. 2021 Feb;60(1):545-548
pubmed: 32851419
Front Endocrinol (Lausanne). 2020 Jan 10;10:910
pubmed: 31998239
J Clin Endocrinol Metab. 2014 Apr;99(4):1461-9
pubmed: 24423347
Metabolism. 2021 Jun;119:154753
pubmed: 33774074
Lancet Infect Dis. 2022 Dec;22(12):e370-e376
pubmed: 36057267
J Intern Med. 2021 Jan;289(1):97-115
pubmed: 32613681
Lancet Diabetes Endocrinol. 2021 May;9(5):276-292
pubmed: 33798465